What makes RAD-140 different from other SARMs?

RAD-140 has the highest anabolic:androgenic ratio of any SARM — approximately 90:1 vs testosterone's 1:1. It was developed by Radius Health and investigated for breast cancer treatment.

Is RAD-140 FDA approved?

No. RAD-140 is NOT FDA approved. The related compound RAD1901 was investigated for breast cancer but RAD-140 itself never reached FDA approval. All SARMs remain unapproved.

What are the neuroprotective properties of RAD-140?

Preclinical rodent studies show RAD-140 protects dopaminergic neurons against kainic acid-induced seizures and 6-OHDA lesioning. Human data does not exist.

How suppressive is RAD-140?

RAD-140 is one of the more suppressive SARMs. At research doses (10-20mg), testosterone suppression can exceed 50%. Recovery typically takes 4-8 weeks.

What is the half-life of RAD-140?

RAD-140 has an elimination half-life of approximately 16 hours, with some sources reporting up to 20 hours. Most protocols use once-daily dosing.

SARM • Radius Health • 90:1 Anabolic Ratio

RAD-140 (Testolone): The Highest Potency SARM

By MeetPeptide Research Team

Last updated: March 2026

90:1 anabolic to androgenic ratio — the strongest selectivity of any SARM. Investigated by Radius Health for breast cancer. Neuroprotective in preclinical models. Here's the research.

Common Research Dose
(Daily)

Anabolic:Androgenic
Ratio

Elimination Half-Life
(Once-Daily Dosing)

Mechanism

How RAD-140 Works

Highest anabolic:androgenic ratio of any SARM. Powerful muscle-building with fewer androgenic side effects.

🎯

90:1 Anabolic:Androgenic Ratio

~90:1 selectivity vs testosterone's 1:1. Strong anabolic effects with minimized prostate/hair/skin androgenic activity. Investigated for women's breast cancer to avoid masculinizing side effects.

🧠

Neuroprotective Properties

Preclinical studies show protection against kainic acid seizures and 6-OHDA lesioning. Reduced brain damage in rodent models via AR-mediated anti-apoptotic signaling. Human data: none.

🎗️

Breast Cancer Investigation

Radius Health investigated RAD1901 (metabolite) for ER+/AR+ breast cancer. The rationale: AR expression in these cancers, selective activation could slow growth. Phase 2 reached, licensed to Novartis.

⚖️

Potency = Suppression

High AR affinity = significant HPG axis suppression. At 10-20mg research doses, testosterone drops 50%+. Among the more suppressive SARMs. Recovery: 4-8 weeks. PCT recommended.

Research Data

What the Research Shows

Data context: Most efficacy data from rodent studies. Human muscle-building data at research doses is anecdotal extrapolated from animal models.

Anabolic:Androgenic Ratio (vs Testosterone)

Preclinical profiling showing ~90:1 selectivity

~90:1

Lean Mass Gains (Ovariectomized Rats)

Significant lean mass restoration in rat muscle wasting model

+30%+

Testosterone Suppression (Research Doses)

50%+ suppression at 10-20mg — community reports

~50%+

Liver Enzyme Elevation Risk

Moderate to high at research doses

Moderate

Safety

Side Effects & Risks

⚠️

Hormonal & Liver

Strong testosterone suppression (50%+ at research doses)
Significant LH/FSH reduction
Liver enzyme elevation (ALT/AST)
Long half-life = slow washout
PCT commonly recommended

📊

Other Effects

HDL cholesterol reduction
Lipid profile changes
Headaches reported
Water retention possible
Acne in some users

Sources

Study Citations

Preclinical — Anabolic Ratio

Pharmacological characterization of RAD140 — a novel nonsteroidal SARM

Neuroendocrine Letters, 2010

NEL 2010

Neuroprotection Study

Neuroprotective effects of RAD140 in kainic acid-induced seizure model

Brain Research, 2017

Brain Res 2017

Breast Cancer Program

RAD1901 (esteliclent) Phase 2 trial for ER+/AR+ breast cancer

ClinicalTrials.gov, Radius Health

NCT02417645

🎯 Who Is This For?

✅ Good Candidate If You...

• Want the strongest anabolic SARM available for lean mass research
• Are interested in body recomposition — building muscle while reducing fat
• Understand the need for PCT and blood work monitoring
• Have experience with SARMs or performance compounds and understand the risks

❌ Not Ideal If You...

• Are a beginner to performance compounds — RAD-140 is one of the most suppressive SARMs
• Have liver concerns — RAD-140 elevates liver enzymes (ALT/AST) at research doses
• Want to maintain fertility — significant testosterone and LH/FSH suppression occurs
• Are pregnant, breastfeeding, or under 25 — hormonal disruption risk is high
• Compete in WADA-tested sports — all SARMs are banned substances

⚕️ Always consult a healthcare provider before starting any peptide protocol.

Bottom Line

Key Takeaways

✅ What We Know

Highest anabolic:androgenic ratio (~90:1) of any SARM
Preclinical neuroprotection data in rodents
Investigated for ER+/AR+ breast cancer
More potent than Ostarine/LGD-4033 mg-for-mg
16-hour half-life allows daily dosing

⚠️ What We Don't Know

Human muscle-building data at research doses
Long-term liver toxicity at 10-20mg
Recovery timeline without PCT
Quality of research chemical supply
Cardiovascular effects long-term

🔬 Verified Research Source

Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.

🧬 RAD-140 Buy from Swiss Chems — Lab-tested, verified purity → Shop Now

Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.

Get the Guide →

⚠️ Disclaimer

Educational only. Not medical advice. RAD-140 is NOT FDA approved. Banned by WADA. Consult healthcare provider. MeetPeptide does not sell SARMs.